相关实验视频
Updated: Jul 6, 2026
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
12.9K
阿尔法阿格尔酶对法布里病左心室缩的长期影响
Gustavo Ferrari1, Isaac Kisinovsky2, Ricardo Reisin3
1Hospital Británico de Buenos Aires, Argentina. E-mail:
Medicina
|June 22, 2024
概括
酶替代疗法 (ERT) 与阿加尔酶α稳定左心室缩在大多数法布里病患者. 这种心脏形态学稳定性是法布里病长期ERT的关键积极结果.
科学领域:
- 生物化学 生物化学
- 遗传学 遗传学 是一个
- 心脏病学 心脏病学
背景情况:
- 费布里病 (FD) 是一种X链 lysosomal储存障碍,影响糖类脂代谢.
- 心脏参与,主要是左心室缩 (LVH),在FD中很常见,导致严重的并发症.
- 在纤维化之前的早期酶替代疗法 (ERT) 与改善的心脏结果有关.
研究的目的:
- 评估每年左心室质量指数 (LVMI) 变化率的评估,该指数是用AGALSIDASEALFA治疗的FD患者.
- 为了确定LVMI的发病率,稳定性,回归或随时间推移的进展.
主要方法:
- 对49名FD患者进行了回顾性观察性研究,他们接受了至少2年的阿加尔酶阿尔法治疗.
- 分析重点关注LVMI和LVMI总体状况的年度变化.
- 随访时间的中位数为7年.
主要成果:
- 在LVMI的整体变化是微小的 (0.38g/m2.73/年).
- 在98%的患者中,长期使用阿加尔酶α的ERT导致LVMI稳定.
- LVMI 稳定独立于基线 LVH,性别,ERT 开始时的年龄和其他心血管风险因素.
结论:
- 在法布里病中,长期使用阿甲酶α的ERT可促进心脏形态学稳定性.
- 这种LVMI的稳定是ERT的一个显著的积极结果.
- 结果与现有文献一致,并且值得注意的是,这是阿根廷首次进行此类研究.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:25Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...